Headache in patients with a meningioma correlates with a bone-invasive growth pattern but not with cytokine expression.
We included 58 patients with meningioma in a prospective study to analyse the prevalence of and risk factors for different types of meningioma-associated headache. Twenty-three patients (40%) had meningioma-associated headache. Of these, the pain was migraine-like in five (22%) and tension-type headache (TTH)-like in 13 (57%). Sixteen of 21 (76%) experienced relief of pain intensity of at least 50% after 18-24 months. Univariate analysis revealed bone-invasive growth pattern (P = 0.007) as a risk factor for headache and intake of antiepileptic drugs (P = 0.04) or large surrounding oedema (P = 0.04) as possible protective parameters. For migraine-like headache, risk factors were a positive history of migraine (P = 0.009) and bone-invasive growth pattern (P = 0.046) and, for TTH-like headache, only bone-invasive growth pattern (P = 0.009). Binary logistic regression analysis added to assess predictability and interaction effects could not identify a single factor predicting the occurrence of headache in the presence of a meningioma (correct prediction in 74% by a model consisting of bone-invasive growth pattern, history of head surgery, intake of antiepileptic drugs, temporal tumour location and moderate and large surrounding oedema). Analysis of 38 tumour specimens could not confirm the hypothesis that the occurrence of headache correlates with the expression magnitude of signal substances known to be present in meningiomas [stroma cell-derived factor 1, interleukin (IL)-1β, IL-6, vascular endothelial growth factor A] or thought to be relevant to headache/pain pathophysiology [prostaglandin-endoperoxide synthase 2, calcitonin-related polypeptide alpha, nitric oxide synthase (NOS) 1, NOS2A, NOS3, transforming growth factor-alpha, tumour necrosis factor, tachykinin, vasoactive intestinal peptide]. The affection of bone integrity and the expression of molecules thought to be relevant to headache pathophysiology might be important for meningioma-associated headache in predisposed individuals.
Schankin
C J
CJ
Department of Neurology, University of Munich Hospital-Großhadern, Munich, Germany. christoph.schankin@med.uni-muenchen.de
Krumbholz
M
M
Sostak
P
P
Reinisch
V M
VM
Goldbrunner
R
R
Straube
A
A
D000368:Aged; D016207:Cytokines / Q000235:genetics*; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006261:Headache / Q000453:epidemiology / Q000235:genetics / Q000473:pathology; D006801:Humans; D008297:Male; D008577:Meningeal Neoplasms / Q000453:epidemiology / Q000235:genetics / Q000473:pathology; D008579:Meningioma / Q000453:epidemiology / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D015995:Prevalence; D011446:Prospective Studies; D012307:Risk Factors; D012886:Skull / Q000473:pathology
D016207:Cytokines